

# ESMO PRECEPTORSHIP PROGRAMME

## GASTROESOPHAGEAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

**Lima, Peru**  
**9-10 April 2025**

---

**CO-CHAIRS:** Paola Montenegro, Peru  
Elizabeth Smyth, United Kingdom

**SPEAKERS:** Cristian Pacheco, Peru  
Erika Ruiz, Mexico  
Marcelo Garrido, Chile  
Andrés Cervantes, Spain  
Florian Lordick, Germany  
Tania Fleitas, Spain  
Alejandro Nieponice, Argentina  
Juan Manuel O'Connor, Argentina  
Guillermo Mendez, Argentina

---

### LEARNING OBJECTIVES

- Understand best clinical practices in the multidisciplinary management of gastroesophageal cancer, both in the neoadjuvant and metastatic settings
- Comprehend the importance of pathology and histo-prognostic factors in the treatment of gastroesophageal cancers
- Learn how to manage patients after disease progression, addressing side effects of treatments and special situations
- Gain insights into the evolving field of biomarker-targeted therapy and immunotherapy for gastroesophageal cancer

---

### ACCREDITATION

The programme of this event will be accredited with **XX ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 9 April 2025

|                           |   |   |
|---------------------------|---|---|
| <b>14:30-14:45</b><br>15' | <b>Welcome and introduction</b>   | <b>Chairs:</b><br><b>Paola Montenegro, PE</b><br><b>Elizabeth Smyth, UK</b>     |
| <b>14:45-16:05</b><br>80' | <b>SESSION 1</b><br><b>Epidemiology/genetics</b>                                  | <b>Chairs:</b><br><b>Florian Lordick, DE</b><br><b>Juan Manuel O'Connor, AR</b> |
| 15'                       | Epidemiology of gastroesophageal cancer in Latin America                          | Cristian Pacheco, PE  |
| 20'                       | Biology and biomarkers in gastroesophageal cancer                                 | Tania Fleitas, ES   |
| 15'                       | Microbiota influence in gastroesophageal cancer                                   | Erika Ruiz, MX  |
| 15'                       | Discussion  | All   |
| <b>16:05-16:35</b>        | <b>Coffee break</b>   |   |
| <b>16:35-17:55</b><br>80' | <b>SESSION 2</b><br><b>Operable Gastroesophageal Cancer Cancer</b>                | <b>Chairs:</b><br><b>Paola Montenegro, PE</b><br><b>Andrés Cervantes, ES</b>    |
| 20'                       | Gastroesophageal junction cancer Chemo vs Chemo radiotherapy                      | Juan Manuel O'Connor, AR  |
| 20'                       | Should immunotherapy be used in operable gastroesophageal adenocarcinoma?         | Elizabeth Smyth, UK   |
| 20'                       | Surgery for gastric and gastroesophageal junction cancer, which surgery and when? | Alejandro Nieponice, AR   |
| 30'                       | Participants clinical case discussion (2x15')                                     | Faculty   |
| <b>20:00</b>              | <b>Networking Dinner</b>  |   |

## Thursday, 10 April 2025

|                           |   |   |
|---------------------------|---|---|
| <b>10:00-11:10</b><br>70' | <b>SESSION 3</b><br><b>Treatment of advanced disease</b>                        | <b>Chairs:</b><br><b>Tania Fleitas, ES</b><br><b>Erika Ruiz, MX</b> |
| 20'                       | Chemotherapy for advanced gastric cancer; doublet and triplet, elderly patients | Florian Lordick, DE   |
| 20'                       | Second line and third line treatments   | Paola Montenegro, PE  |
| 30'                       | Participants clinical case discussion (2x15')                                   | Faculty   |
| <b>11:10-11:40</b>        | <b>Coffee break</b>   |   |

|                                  |  |  |
|----------------------------------|--|--|
| <b>11:40-13:00</b><br><b>80'</b> | <b>SESSION 4</b><br><b>Biomarker targeted therapy and immunotherapy</b>                                      | <b>Chairs:</b><br><b>Elizabeth Smyth, UK</b><br><b>Alejandro Nieponice, AR</b> |
| 20'                              | Sequencing HER2 directed therapy   | Andrés Cervantes, ES   |
| 20'                              | Immunotherapy new challenges   | Marcelo Garrido, CL  |
| 20'                              | Emerging therapies; claudin 18.2, FGFR2 etc  | Tania Fleitas, ES  |
| 20'                              | Discussion   | Faculty  |
| <b>13:00-14:00</b>               | <b>Lunch</b>   |  |
| <b>14:00-15:30</b><br><b>90'</b> | <b>SESSION 5</b><br><b>Oligometastatic gastroesophageal cancer</b>   | <b>Chairs:</b><br><b>Erika Ruiz, MX</b><br><b>Andrés Cervantes, ES</b>         |
| 40'                              | DEBATE: Patients with oligometastatic gastroesophageal cancer should be surgical candidates<br>- YES<br>- NO | Alejandro Nieponice, AR<br>Guillermo Mendez, AR                                |
| 30'                              | Participants clinical case discussion (2x15')  | Faculty  |
| 20'                              | Discussion   | All  |
| <b>15:30-16:00</b>               | <b>Coffee break</b>  |  |
| <b>16:00-17:00</b><br><b>60'</b> | <b>SESSION 6</b><br><b>Challenging Clinical Situations</b>   | <b>Chairs:</b><br><b>Marcelo Garrido, CL</b>                                   |
| 5'                               | Case Presentation<br>Case of squamous cell cancer: to operate or not to operate?                             | Guillermo Mendez, AR   |
| 15'                              | Discussion   | All  |
| 5'                               | Case Presentation<br>Case of gastric cancer signet ring cells that requires neoadjuvant therapy              | Paola Montenegro, PE   |
| 15'                              | Discussion   | All  |
| 5'                               | Case Presentation<br>Case of gastric cancer with neoadjuvant therapy operated without response               | Florian Lordick, DE  |
| 15'                              | Discussion   | All  |
| <b>17:00-17:10</b><br><b>10'</b> | <b>Closing remarks</b>   |  |
| 10'                              | Closing and final remarks  | Paola Montenegro, PE<br>Elizabeth Smyth, UK                                    |

**Note:** Each 15-minute slot for clinical case discussion includes 5' case presentation and 10' Q&A / panel discussion